10x Genomics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving 10x Genomics, Inc. now
Current reporting with the operating signal separated from the noise.
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
Investors are testing whether 10x Genomics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript
Investors are testing whether 10x Genomics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.10x Genomics, Inc. v. Illumina, Inc.
The story matters when it changes 10x Genomics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.10x Genomics, Inc. (TXG): Among the Best Genomics Stocks to Buy Right Now
Investors are testing whether 10x Genomics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest TXG filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
10x Genomics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →